Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,556.37
-0.4%
-24.63
Arrow-Thin-Down
DJI
46,124.06
-0.2%
-84.41
Arrow-Thin-Down
NASDAQ
21,761.89
-0.8%
-184.87
Arrow-Thin-Down
Bitcoin
$70,491.00
+0.1%
+$61.48
Arrow-Thin-Down
AMZN
$207.10
-1.4%
-$3.04
Arrow-Thin-Down
GOOG
$289.30
-3.3%
-$9.72
Arrow-Thin-Down
META
$592.51
-1.9%
-$11.55
Arrow-Thin-Down
MSFT
$372.37
-2.8%
-$10.63
Arrow-Thin-Down
NVDA
$175.07
-0.3%
-$0.57
Arrow-Thin-Down
TSLA
$383.03
+0.6%
+$2.18
Most Active StocksDaily Stock GainersDaily Stock Losers

Is Teva Just Looking Out for Itself

It sent the FDA a citizens' petition regarding a pending competitor.

By Dave Williamson – Jan 11, 2013 at 7:08PM EST

Is Teva (TEVA +1.29%) genuinely concerned about Biogen's  (BIIB +0.15%) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.

Read Next

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
XMFGreenwave4
X@motleydavid

Stocks Mentioned

Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
NYSE: TEVA
$29.14
(+1.29%)+$0.37
Novartis Stock Quote
Novartis
NYSE: NVS
$148.51
(+0.28%)+$0.42
Biogen Stock Quote
Biogen
NASDAQ: BIIB
$183.92
(+0.15%)+$0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services